Copper (64Cu) oxodotreotide
| Clinical data | |
|---|---|
| Trade names | Detectnet |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| License data | |
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C65H88CuN14O19S2 |
| Molar mass | 1497.16 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Copper (64Cu) oxodotreotide or Copper Cu 64 dotatate, sold under the brand name Detectnet, is a radioactive diagnostic agent used with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors in adults.
Common side effects include nausea, vomiting and flushing.
It was approved for medical use in the United States in September 2020.